Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.50 |
| ▸ | OGA | O60502 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MLNR | O43193 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4432680 | 0.88 | HRH4 (0.47) | GPR119OGAHSD17B10ALDH1A1GAA | |
| SCHEMBL14138626 | 0.86 | GPR119 (0.62) | GPR119OGAHSD17B10ALDH1A1MLNR | |
| SCHEMBL16431015 | 0.81 | ALDH1A1 (0.52) | GPR119OGAHSD17B10ALDH1A1CYP2D6 | |
| SCHEMBL13212276 | 0.81 | HSD17B10 (0.72) | GPR119OGAHSD17B10ALDH1A1MLNR | |
| SCHEMBL16430343 | 0.81 | KCNJ1 (0.49) | GPR119OGAHSD17B10ALDH1A1CYP2D6 | |
| SCHEMBL16438706 | 0.81 | HDAC1 (0.49) | GPR119OGAHSD17B10ALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL16430655 | 0.80 | HDAC1 (0.48) | GPR119OGAHSD17B10ALDH1A1CYP2D6 | |
| SCHEMBL7489968 | 0.80 | CHRNA7 (0.54) | HSD17B10ALDH1A1MLNRCYP2D6PLD1 | |
| SCHEMBL16431467 | 0.79 | ALDH1A1 (0.57) | GPR119HSD17B10ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL649950 | 0.79 | OGA (0.48) | GPR119OGAHSD17B10ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1867554-B | Piperazine with ortho-substituted phenyl and its use as GLYT1 inhibitors | HOFFMANN LA ROCHE | 2011-07-06 | — | — | CN | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| EP-1909791-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007003964-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| CN-1867554-A | Piperazine with ortho-substituted phenyl and its use as GLYT1 inhibitors | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | GPR119 1/4885OGA 1305/4885HSD17B10 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.